{"id":"duobrii-0-01-0-045-topical-lotion","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Application site burning"},{"rate":null,"effect":"Application site pruritus"},{"rate":null,"effect":"Skin atrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Halobetasol propionate is a Class I (super-potent) topical corticosteroid that suppresses inflammatory cytokines and immune cell infiltration in the skin. Tazarotene is a third-generation retinoid that binds retinoic acid receptors to promote keratinocyte differentiation and reduce hyperproliferation. The combination provides complementary anti-inflammatory and anti-proliferative effects for enhanced efficacy in plaque psoriasis.","oneSentence":"Duobrii combines halobetasol propionate (a potent corticosteroid) and tazarotene (a retinoid) to reduce inflammation and normalize skin cell differentiation in psoriasis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:16.145Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Plaque psoriasis"}]},"trialDetails":[{"nctId":"NCT05203315","phase":"PHASE3","title":"Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults","status":"COMPLETED","sponsor":"Austin Institute for Clinical Research","startDate":"2022-01-13","conditions":"Plaque Psoriasis","enrollment":21},{"nctId":"NCT05282771","phase":"EARLY_PHASE1","title":"A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2021-04-16","conditions":"Plaque Psoriasis","enrollment":402}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Duobrii 0.01 % / 0.045 % Topical Lotion","genericName":"Duobrii 0.01 % / 0.045 % Topical Lotion","companyName":"Austin Institute for Clinical Research","companyId":"austin-institute-for-clinical-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Duobrii combines halobetasol propionate (a potent corticosteroid) and tazarotene (a retinoid) to reduce inflammation and normalize skin cell differentiation in psoriasis. Used for Plaque psoriasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}